• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Frataxin (FXN) Antibody – Rabbit Polyclonal

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS618238

Elemental iron is required for a variety of normal cellular functions and vital for proper growth and development. However, natural iron is quite insoluble and excess iron is harmful, since it can catalyze the formation of potentially damaging reactive oxygen… More details

$545 / 0.05 mg +1 FREE 8GB USB
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Frataxin (FXN), Polyclonal Antibody
Full Product Name
Frataxin (FXN)
Product Gene Name
Product Synonym Names
Anti -Frataxin (FXN)
Clonality
Polyclonal
Isotype
IgG
Host
Rabbit
Species Reactivity
Mouse
Form/Format
Supplied as a liquid in PBS, pH 7.5, 0.1% BSA.
Purity/Purification
Affinity Purified
Purified by immunoaffinity chromatography.
Concentration
1mg/ml (lot specific)
Specificity
Recognizes mouse Frataxin (FXN).
Preparation and Storage
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Molecular Weight
7,201 Da
Chromosome Location
chromosome: 9; Location: 9q21.11
3D Structure
ModBase 3D Structure for O96034
Immunogen
A synthetic peptide corresponding to 20aa within the C-terminus of mouse FXN (KLH).
Species Sequence Homology
Human, 94%
Control Peptide
Frataxin, Mouse, Control Peptide (FXN)

Product Categories/Family for anti-FXN antibody

Applications Tested/Suitable for anti-FXN antibody
ELISA (EL/EIA), Western Blot (WB)
Application Notes for anti-FXN antibody
Suitable for use in ELISA. Other potential application, though not tested is Western Blot. Other applications not tested.

ELISA: 1:100,000 using 50-100ng control peptide/well Optimal dilutions to be determined by the researcher.

Other Notes

Small volumes of anti-FXN antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for FXN purchase

MBS618238 is an antibody targeting FXN. Also known as Frataxin (FXN). Reactive in Mouse. Host: Rabbit.

Additional Details

NCBI/Uniprot data below describe general gene information for FXN. It may not necessarily be applicable to this product.

NCBI GI #
NCBI GeneID
UniProt Primary Accession #
UniProt Related Accession #
NCBI Official Full Name
frataxin
NCBI Official Synonym Full Names
frataxin
NCBI Official Symbol
FXN
NCBI Official Synonym Symbols
FA; X25; CyaY; FARR; FRDA; MGC57199; FXN
UniProt Protein Name
Frataxin
Protein Family
UniProt Gene Name
x25
UniProt Entry Name
O96034_HUMAN
NCBI Protein Information
frataxin, mitochondrial; OTTHUMP00000215688; friedreich ataxia protein

NCBI Summary for FXN

This nuclear gene encodes a mitochondrial protein which belongs to FRATAXIN family. The protein functions in regulating mitochondrial iron transport and respiration. The expansion of intronic trinucleotide repeat GAA results in Friedreich ataxia. Alternative splicing results in multiple transcript variants. [provided by RefSeq]
Show more

UniProt Comments for FXN

FXN: Promotes the biosynthesis of heme and assembly and repair of iron-sulfur clusters by delivering Fe(2+) to proteins involved in these pathways. May play a role in the protection against iron-catalyzed oxidative stress through its ability to catalyze the oxidation of Fe(2+) to Fe(3+); the oligomeric form but not the monomeric form has in vitro ferroxidase activity. May be able to store large amounts of iron in the form of a ferrihydrite mineral by oligomerization; however, the physiological relevance is unsure as reports are conflicting and the function has only been shown using heterologous overexpression systems. Modulates the RNA-binding activity of ACO1. Defects in FXN are the cause of Friedreich ataxia (FRDA). FRDA is an autosomal recessive, progressive degenerative disease characterized by neurodegeneration and cardiomyopathy it is the most common inherited ataxia. The disorder is usually manifest before adolescence and is generally characterized by incoordination of limb movements, dysarthria, nystagmus, diminished or absent tendon reflexes, Babinski sign, impairment of position and vibratory senses, scoliosis, pes cavus, and hammer toe. In most patients, FRDA is due to GAA triplet repeat expansions in the first intron of the frataxin gene. But in some cases the disease is due to mutations in the coding region. Belongs to the frataxin family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Mitochondrial; Motility/polarity/chemotaxis; EC 1.16.3.1

Chromosomal Location of Human Ortholog: 9q21.11

Cellular Component: mitochondrion; mitochondrial matrix; cytosol

Molecular Function: ferroxidase activity; 2 iron, 2 sulfur cluster binding; protein binding; ferric iron binding; ferrous iron binding; iron-sulfur cluster binding

Biological Process: mitochondrion organization and biogenesis; negative regulation of multicellular organism growth; cellular iron ion homeostasis; positive regulation of metalloenzyme activity; proprioception; positive regulation of transferase activity; negative regulation of organ growth; positive regulation of cell growth; adult walking behavior; embryonic development ending in birth or egg hatching; protein autoprocessing; iron incorporation into metallo-sulfur cluster; positive regulation of lyase activity; positive regulation of cell proliferation; aerobic respiration; ion transport; response to iron ion; negative regulation of apoptosis; positive regulation of oxidoreductase activity; heme biosynthetic process; oxidative phosphorylation

Disease: Friedreich Ataxia 1
Show more

Research Articles on FXN

1. these results suggest an important role for eEF1A2 in driving cap-independent translation of utrophin A in skeletal muscle.
2. there is a a severe depletion of CTCF in the 5'UTR of the FXN gene in FRDA, and coincident heterochromatin formation involving the +1 nucleosome via enrichment of H3K9me3 and recruitment of heterochromatin protein 1
3. Data show that -terminus region is flexible and intrinsically unfolded in human frataxin.
4. frataxin deficiency triggers inflammatory changes and death of Schwann cells that is inhibitable by inflammatory and anti-apoptotic drugs.
5. Molecular genetic studies revealed that all Friedreich's ataxia patients in the Paphos district of Cyprus had the most common mutation, a homozygous expansion of the GAA triplet repeat in the first intron of the frataxin gene.
6. Azelaoyl PAF significantly increases the intracellular frataxin levels by twofold in the neuroblastoma cell line SKNBE and fibroblasts from FRDA patients and Azelaoyl PAF increases frataxin protein through a transcriptional mechanism.
7. The PPARG pathway is dysregulated in frataxin deficient mice and Friedreich's ataxia patients.
8. Regulatory effects of recombinant human erythropoietin occur at the post-translational level.
9. identification nof a novel point mutation (c.165 + 1 G ] A) which involves the consensus GT dinucleotide in the 3'splice acceptor site of intron 1 of the frataxin gene in two compound heterozygous siblings with Friedreich ataxia
10. We did not find any mutations or polymorphisms, nor expansion of the intronic trinucleotide repeat of the frataxin gene in refractory anemia with ring sideroblasts
Show more

Precautions

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

Disclaimer

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.

Product Note

Select online data sheet information is drawn from bioinformatics databases, occasionally resulting in ambiguous or non-relevant product information. It is the responsibility of the customer to review, verify, and evaluate the information to make sure it matches their requirements before purchasing the kit. Our ELISA Kit assays are dynamic research tools and sometimes they may be updated and improved. If the format of this assay is important to you then please request the current manual or contact our technical support team with a presales inquiry before placing an order. We will confirm the current details of the assay. We cannot guarantee the sample manual posted online is the most current manual, it is intended to serve as an example only. Please refer to the instructions For Use provided with the assay kit for precise details.

Product PubMed Publications

Pathways associated with anti-FXN antibody

Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000